---
title: "688136.SH (688136.SH) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/688136.SH/news.md"
symbol: "688136.SH"
name: "688136.SH"
parent: "https://longbridge.com/zh-CN/quote/688136.SH.md"
datetime: "2026-03-18T01:31:03.928Z"
locales:
  - [en](https://longbridge.com/en/quote/688136.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688136.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688136.SH/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/688136.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688136.SH/news.md)


# 688136.SH (688136.SH) — 相关新闻

### [Huahaipharm's subsidiary has obtained the drug registration certificate for concentrated oral solution of sodium magnesium sulfate](https://longbridge.com/zh-CN/news/278365993.md)
*2026-03-09T09:39:14.000Z*
> Huahaipharm's holding subsidiary, Changxing Pharmaceutical, recently obtained the drug registration certificate for sodi

### [](https://longbridge.com/zh-CN/news/278347924.md)
*2026-03-09T07:30:28.000Z*
> The National Bureau of Statistics report shows that in February, the CPI rose by 1.3% year-on-year, and the core CPI inc

### [SDKX's overseas product albumin paclitaxel has been approved in multiple regions](https://longbridge.com/zh-CN/news/278337252.md)
*2026-03-09T06:02:23.000Z*
> SDKX and Haichang Biotechnology's anti-tumor product injectable paclitaxel (albumin-bound) Apexelsin has recently obtain

### [Future Health Industry Weekly Report (02.27 - 03.06): Pharmaceutical Industry Dynamics](https://longbridge.com/zh-CN/news/278189047.md)
*2026-03-07T02:09:16.000Z*
> This week's pharmaceutical industry updates include: Jet Bio-Filtration acquired 70% equity of Jieke Membrane for 7.9198

### [SDKX: The GB19 injection for skin lupus erythematosus has received the drug clinical trial approval notice](https://longbridge.com/zh-CN/news/277610927.md)
*2026-03-03T11:20:11.000Z*
> SDKX announced that its wholly-owned subsidiary Shenzhen SDKX Pharmaceutical has received approval from the National Med

### [SDKX: Completed a share repurchase of 55.0646 million yuan, accounting for 0.75% of the total share capital](https://longbridge.com/zh-CN/news/277605152.md)
*2026-03-03T10:37:39.000Z*
> SDKX announced that the company will implement a share repurchase from March 17, 2025, to March 3, 2026, having repurcha

### [SDKX has obtained approval for the marketing of its product, Carbonate Suvilam Tablets, in Peru](https://longbridge.com/zh-CN/news/277542306.md)
*2026-03-03T01:13:55.000Z*
> SDKX and Xinhua Pharm's collaboration on Sevelamer Carbonate Tablets has received marketing approval from the Peruvian N

### [SDKX: The net profit for 2025 is expected to be 159 million yuan](https://longbridge.com/zh-CN/news/277176007.md)
*2026-02-27T09:43:28.000Z*
> SDKX announced that the company achieved an operating income of 1,541,156.4 thousand yuan in 2025, a year-on-year increa